We examined genetic associations with duloxetine response in generalized anxiety disorder (GAD). Three pooled studies in patients with GAD receiving duloxetine 60-120 mg per day (N ¼ 164) or placebo (N ¼ 95) were used. Associations between 825 single-nucleotide polymorphisms (SNPs) in 61 candidate genes with change in Hamilton Anxiety Scale scores were examined with set-based testing (adjusted for the number of SNPs within each gene); sets with two-sided adjusted Pp0.05 were examined using repeated measure analysis. Follow-up analysis explored associations of these SNPs with change in Hamilton Rating Scale for Depression-Anxiety Subscale in a 6-week study in duloxetine-treated patients with major depressive disorder (MDD) (N ¼ 241). Variants in corticotropin-releasing hormone receptor 1 (CRHR1), dopamine receptor D3 (DRD3), nuclear receptor subfamily group C, member 1 (NR3C1) and phosphodiesterase 1A (PDE1A) were associated with duloxetine response in GAD. Only rs4792888 in CRHR1 showed modest evidence of association with duloxetine response in MDD (P ¼ 0.029 in GAD, P ¼ 0.054 in MDD). In conclusion, CRHR1 variation merits investigation in pathophysiology of anxiety and its treatment response.
Introduction
Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are two common disorders that can be treated successfully with antidepressants. 1 However, high inter-individual variations of improvement in response to treatment have been observed. Genetic factors seem to be one variable influencing treatment outcome. 2 Multiple common variations have been reported to be associated with antidepressant responsiveness, including one in catechol-O-methyltransferase (COMT) with duloxetine treatment. 3 Of special interest are genes involved in the hypothalamic-pituitary-adrenal (HPA) axis, as it has been proposed that the HPA axis might be involved in the pathogenesis of both depression 4 and anxiety disorders. 5 Polymorphisms in genes coding several members of the HPA axis have been associated with treatment response in patients with MDD (for example, corticotropin-releasing hormone receptor 1 (CRHR1), 4 CRHR2, 4 NR3C1, 6 FKBP5 7 and CREB1 8 ). Recently, Lenze et al. 9 demonstrated that polymorphisms in the serotonin transporter are associated with variability in the efficacy of treatment with selective serotonin reuptake inhibitors in older patients with GAD. Although twin studies suggest similarity in genetic risk between MDD and GAD, 10 and pharmacological treatments are similar, to our knowledge no previous study has investigated shared pharmacogenetical predictors for MDD and GAD treatment response.
Here, we tested the hypothesis that variations in candidate genes functionally related to antidepressant mechanism of action are associated with improvement of anxiety symptoms in patients with GAD during treatment with duloxetine. In the absence of a replication cohort, we then examined these variants for association with response of anxiety symptoms to duloxetine in MDD. We also examined these same variants for association with improvement of anxiety symptoms in the placebo-treated cohort of the GAD study.
Materials and methods
All study protocols were approved by individual institutional review boards before enrolling any patients, and all patients provided written informed consent before receiving study therapy or undergoing study procedures.
Patients and study design
We utilized self-identified white patients from four clinical trials who consented to genetic testing. Patients from studies 1 through 3 were diagnosed with GAD, whereas patients from study 4 had MDD. All patients were adults (X18-yearold) and received duloxetine 60-120 mg (flexible dosing in studies 1 through 3: dose could be increased to improve efficacy) once daily for 10 weeks (studies 1 and 2), 12 weeks (study 3) or 6 weeks (study 4). Studies 1, 2 and 4 were double blind, while the open-label duloxetine lead-in phase before double-blind randomization in study 3 was used. Studies 1 and 2 were placebo-controlled. Detailed descriptions of study procedures, inclusion and exclusion criteria were published previously. [11] [12] [13] [14] Briefly, at study enrollment patients were required to have a Clinical Global Impression-Severity score X4, a Covi Anxiety Scale score X9, all items in the Raskin Depression Scale p3, a Covi Anxiety Scale score 4Raskin Depression Scale score and a Hospital Anxiety and Depression Scale anxiety subscale score X10 in studies 1 through 3. In study 4, patients were required to have a 17-item Hamilton Rating Scale for Depression (HAMD-17) score X15 at study enrollment. Patients with anxiety disorders as comorbidities were not excluded from study 4. Concomitant medications with primarily central nervous system activity were not allowed in studies 2 and 3. In study 1, concomitant medications were recorded and compared among treatment groups. In study 4, concomitant medications with a sedative effect were excluded.
Eligible patients from studies 1 through 3 were pooled for the GAD cohort and eligible patients from study 4 were used as the MDD cohort. Changes in anxiety were quantified with the Hamilton Anxiety Scale (HAM-A) in the GAD cohort, and the Hamilton Rating Scale for DepressionAnxiety subscale (HAMD-Anxiety subscale) in the MDD cohort. Only patients with 85% of usable calls across all examined single-nucleotide polymorphisms (SNPs) were used in the analyses.
Genotyping
Candidate SNPs and genes were selected on the basis of prior reports of genetic associations in the literature and on observations in previous association studies performed by the authors. Genotyping was performed by Cogenics (Newton, MA, USA) using the MassArray (Sequenom Inc., San Diego, CA, USA) platform. 15 Only SNPs with X85% usable calls across patients (35 SNPs were removed because of o85% usable calls across patients), and with minor allele frequencies of X1% were examined (64 autosomal and 1 Xchromosomal SNPs were removed because of minor allele frequencies ¼ 0%). Patients were removed if they failed genotyping for X85% of their SNPs, and male patients heterozygous for X-chromosomal SNPs were removed. A total of five patients were excluded from the analyses owing to failed genotyping (four placebo patients and one duloxetine patient).
Hardy-Weinberg equilibrium (P40.0001) was tested and SNPs out of Hardy-Weinberg equilibrium were flagged, but not removed. Monomorphic SNPs were removed, and correlations among patients were checked.
Statistical analyses
Associations of 825 SNPs in 61 candidate genes with percent changes in HAM-A total scores (items 1-14) were examined in both duloxetine and placebo groups in the GAD cohort after adjusting for baseline total score (Supplementary Table 1 ). Genotype was coded under an additive model (genotype was coded as 0, 1 or 2 based on the number of variant alleles), and the impact of the SNPs in the GAD cohort was tested using set-based testing (PLINK, version 1.07; http:// pngu.mgh.harvard.edu/purcell/plink/) 16 with adjustment for the number of SNPs examined within each gene and for baseline HAM-A. Sets of SNPs in genes that produced adjusted two-sided P-values of p0.05 were then examined in a mixed model repeated measures (MMRM) analysis after adjusting for baseline HAM-A, week, genotype by week and study identifier.
The impact of SNPs that produced P-values of p0.05 from two-sided testing in the GAD cohort were also examined in the placebo-treated GAD cohort using similar methodology, and in the MDD cohort using MMRM analysis after adjusting for baseline HAMD-Anxiety subscale, week, therapy, food group (in the MDD trial, patients were assigned to take study drug with or without a meal), therapy by food group, genotype (coded as 0, 1 or 2) and genotype by week. An SNP was considered significantly associated with change in anxiety if the one-sided P-value in the MDD analysis was p0.05 and the direction of the effect was the same as that seen in the GAD analysis. MMRM analyses for baseline to end point changes in HAM-A and HAMD-Anxiety subscale were done with SAS Proc Mixed (SAS 9.1.3, SAS Institute, Cary, NC, USA). Among the SNPs tested for associations with anxiety improvement in both the GAD and the MDD cohorts were five COMT SNPs (rs165737, rs165774, rs174696, rs174697 and rs165599), previously associated with depression improvement in the MDD cohort. 3 
Results

Demographics
The numbers of self-reported white patients who consented to genetic testing and who were included in the current analyses were 54, 56 and 54 in studies 1, 2 and 3, respectively, for duloxetine, and 58 and 37 in studies 1 and 2, respectively, for placebo; the resulting GAD cohort included a total of 164 duloxetine-treated patients and 95 placebo-treated patients. In study 4, a total of 241 selfreported white patients treated with duloxetine consented to genetic testing and were included in the MDD cohort. Overall, GAD and MDD cohorts displayed similar baseline demographics (Supplementary Table 2 ).
Association analysis of candidate genes
Set-based testing resulted in corrected Pp0.05 for 12 SNPs in four genes for association with change in HAM-A in the duloxetine group of the GAD cohort (Table 1) ; no other candidate SNPs showed significant associations, which might be caused by type I or II error. In the MDD cohort, repeated measures analysis (MMRM) (rather than last observation carried forward analysis because of increased statistical power to detect differences) of the SNPs identified by PLINK revealed only one SNP, rs4792888, in CRHR1, potentially associated with anxiety improvement during treatment with duloxetine in both cohorts, but only marginally significant in the MDD group (one-tailed P ¼ 0.029 in GAD, P ¼ 0.054 in MDD) ( Table 2 ). Analysis of least-squares mean changes stratified by rs4792888 genotype showed consistent least-squares mean differences between genotypes in the GAD and MDD cohorts for AA and AG genotypes, with inconclusive results for GG, which occurred in only three patients for each cohort (Figures 1a  and b) . However, an additional CRHR1 SNP and four dopamine receptor D3 (DRD3) SNPs had nominal Po0.05 for association with anxiety response in GAD (shown with associated changes in HAM-A score in Table 3 ) with setbased testing and with MMRM analysis. rs258747 in NR3C1 had P ¼ 0.033 by MMRM analysis for association with change in HAMD-Anxiety in the MDD cohort versus nonsignificance by MMRM analysis for P-values based on association between change in Hamilton Rating Scale for Depression-Anxiety Subscale and SNPs.
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change in HAM-A in the GAD cohort. Additionally, analysis of the direction of change for the individual genotypes revealed that the TT genotype had the greatest decrease of HAM-A total score compared with the CC and the CT genotypes in the GAD cohort (À17.3, À14.8 and À15.9, respectively), whereas the TT genotype had the smallest decrease in HAMD-Anxiety subscale total score compared with the CC and CT genotypes in the MDD cohort (À1.5, À2.6 and À2.3, respectively). None of the 12 SNPs discussed above were significantly associated with anxiety improvement during placebo treatment of the GAD cohort. Additionally, none of the examined COMT SNPs showed significant associations with anxiety improvement in the duloxetine group of the GAD cohort, although two were associated with anxiety improvement in the placebo group of the GAD cohort (Supplementary Table 3 ). In the MDD cohort, four of five COMT SNPs showed significant associations with HAMD-Anxiety subscale score change (Supplementary Table 3 ).
Discussion
Our analyses identified an intronic SNP in CRHR1, which is statistically significantly associated with anxiety improvement in patients with GAD and shows a similar effect in MDD. COMT SNPs that were previously identified as being significantly associated with improvement of depressive symptoms during treatment with duloxetine in patients with MDD showed no significant associations with anxiety improvement in duloxetine-treated patients with GAD. However, these SNPs did show significant associations with anxiety improvement in the MDD cohort. Surprisingly, two of the examined COMT SNPs, including rs165599, were associated with anxiety improvement during placebo treatment of GAD. Evaluation of associations of these SNPs with depression improvement in MDD data sets during placebo treatment (not available in the previously assessed duloxetine study data set) 3 is warranted. Polymorphisms in CRHR1, the gene encoding the corticotropin-releasing hormone receptor type 1, have been associated with alterations in the HPA axis that might increase vulnerability to depression and anxiety disorders. 17 Examples include the promoter SNP rs12938031, the intron-1 SNP rs12936181 and the intron-4 SNP rs81189, which were shown to moderate the HPA axis response to stress. 18 Additionally, intron-2 SNP rs110402 and intron-3 SNP Figure 1 (a) LS Mean changes in HAM-A total score stratified by CRHR1 SNP rs4792888 genotype in the GAD cohort. (b) LS Mean changes in HAMD-Anxiety total score stratified by CRHR1 SNP rs4792888 genotype in the MDD cohort. Abbreviations: CRHR1, corticotropin-releasing hormone receptor 1; GAD, generalized anxiety disorder; HAM-A, Hamilton Anxiety Scale; HAMD-Anxiety, Hamilton Rating Scale for Depression-Anxiety Subscale; LS Mean, least-squares mean; MDD, major depressive disorder; n, number of patients; SNP, single nucleotide polymorphism. Table 3 19 rs110402 in CRHR1 has been associated with an increased risk for depression with a seasonal pattern and an early age of onset. 4 An increased response to fluoxetine was observed in patients with MDD and high levels of anxiety if they were (a) homozygous for the CRHR1 GAG haplotype consisting of SNPs intron-14 rs1876828, intron-4 rs242939, and intron-3 rs242941 or (b) carriers of the G/G genotype for rs242941. 20 Similarly, patients homozygous for the CRHR1 GAG haplotype showed a 70% greater reduction in anxiety symptoms (measured with HAM-A) compared with heterozygous patients. 21 Contrary are results from a double-blind, placebo-controlled trial examining the efficacy of pexacerfont, a selective corticotropin-releasing factor-1 receptor antagonist. Pexacerfont did not produce significantly different changes in HAM-A total scores from baseline to an 8-week end point compared with placebo in patients with GAD. 22 Nevertheless, our results provide additional evidence for the importance of CRHR1 in the responsiveness to treatment of anxiety symptoms in patients with MDD or GAD.
Although we have previously reported association between COMT SNPs and response to duloxetine in MDD, no significant associations of either SNP were observed in the duloxetine group of the GAD cohort. This may reflect type I or II error, but it is also possible that this observation reflects pathophysiological differences between MDD and GAD.
The interpretation of our results is limited by several factors. First, only white patients were included (owing to too few study participants with non-white ethnicity). Second, both cohorts had relatively small sample sizes, yielding limited power to detect or confirm associations; for example, if a gene had an effect size of 0.33, the effect size for duloxetine versus placebo in GAD study 1, and 20% of the patients had the good responder genotype, power would only be 33% to detect the gene, even without adjusting for the number of comparisons performed. Additionally, the patient samples were heterogeneous, based on disease state and treatment regimens among studies. The coverage of some candidate genes was limited. Although patient compliance with drug treatment was assessed by patient interviews at site visits, no drug plasma levels were assessed. Different anxiety scales were used in the patient cohorts. Baseline anxiety levels, as measured with HAM-A, in the MDD cohort were lower than in the GAD studies (Supplementary Figure 1 ), which may point to the likelihood of both decreased ability to detect drug response as well as fundamental differences in the expected pattern of response. However, our results are supported by the fact that most of the limitations would bias us toward the null hypothesis.
This pharmacogenetic examination of GAD adds to previous suggestions of the importance of CRHR1 and potentially the HPA axis in anxiety. The associations of genetic variations with anxiety symptom improvement during treatment with duloxetine, if repeated, might facilitate the development of more individualized treatment regimens for specific disorders based on genotype.
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